203 related articles for article (PubMed ID: 20521907)
1. Alternative extrusion-spheronization aids.
Jain SP; Singh PP; Amin PD
Drug Dev Ind Pharm; 2010 Nov; 36(11):1364-76. PubMed ID: 20521907
[TBL] [Abstract][Full Text] [Related]
2. Functionality of cross-linked polyvinylpyrrolidone as a spheronization aid: a promising alternative to microcrystalline cellulose.
Liew CV; Gu L; Soh JL; Heng PW
Pharm Res; 2005 Aug; 22(8):1387-98. PubMed ID: 16078149
[TBL] [Abstract][Full Text] [Related]
3. Production of pellets via extrusion-spheronisation without the incorporation of microcrystalline cellulose: a critical review.
Dukić-Ott A; Thommes M; Remon JP; Kleinebudde P; Vervaet C
Eur J Pharm Biopharm; 2009 Jan; 71(1):38-46. PubMed ID: 18771727
[TBL] [Abstract][Full Text] [Related]
4. Use of chitosan-alginate as alternative pelletization aid to microcrystalline cellulose in extrusion/spheronization.
Charoenthai N; Kleinebudde P; Puttipipatkhachorn S
J Pharm Sci; 2007 Sep; 96(9):2469-84. PubMed ID: 17286294
[TBL] [Abstract][Full Text] [Related]
5. The preparation by extrusion/spheronization and the properties of pellets containing drugs, microcrystalline cellulose and glyceryl monostearate.
Chatchawalsaisin J; Podczeck F; Newton JM
Eur J Pharm Sci; 2005 Jan; 24(1):35-48. PubMed ID: 15626576
[TBL] [Abstract][Full Text] [Related]
6. A study of the effects of the physical characteristics of microcrystalline cellulose on performance in extrusion spheronization.
Heng PW; Koo OM
Pharm Res; 2001 Apr; 18(4):480-7. PubMed ID: 11451035
[TBL] [Abstract][Full Text] [Related]
7. Influence of MCC II fraction and storage conditions on pellet properties.
Krueger C; Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1039-45. PubMed ID: 23872176
[TBL] [Abstract][Full Text] [Related]
8. Use of crospovidone as pelletization aid as alternative to microcrystalline cellulose: effects on pellet properties.
Verheyen P; Steffens KJ; Kleinebudde P
Drug Dev Ind Pharm; 2009 Nov; 35(11):1325-32. PubMed ID: 19832632
[TBL] [Abstract][Full Text] [Related]
9. Effect of microcrystalline cellulose grade and process variables on pellets prepared by extrusion-spheronization.
Alvarez L; Concheiro A; Gómez-Amoza JL; Souto C; Martínez-Pacheco R
Drug Dev Ind Pharm; 2002 Apr; 28(4):451-6. PubMed ID: 12056538
[TBL] [Abstract][Full Text] [Related]
10. Use of extrusion aids for successful production of Kollidon
Loka NC; Saripella KK; Pinto CA; Neau SH
Drug Dev Ind Pharm; 2018 Apr; 44(4):632-642. PubMed ID: 29183166
[TBL] [Abstract][Full Text] [Related]
11. The influence of microcrystalline cellulose grade on shape and shape distributions of pellets produced by extrusion-spheronization.
Koo OM; Heng PW
Chem Pharm Bull (Tokyo); 2001 Nov; 49(11):1383-7. PubMed ID: 11724226
[TBL] [Abstract][Full Text] [Related]
12. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. I. Influence of type and fraction of filler.
Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2006 May; 63(1):59-67. PubMed ID: 16326085
[TBL] [Abstract][Full Text] [Related]
13. Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. II. Influence of drug and filler type.
Thommes M; Kleinebudde P
Eur J Pharm Biopharm; 2006 May; 63(1):68-75. PubMed ID: 16325384
[TBL] [Abstract][Full Text] [Related]
14. Approaches to developing fast release pellets via wet extrusion-spheronization.
Xia Y; Shi CY; Fang JG; Wang WQ
Pharm Dev Technol; 2018 Jun; 23(5):432-441. PubMed ID: 27882815
[TBL] [Abstract][Full Text] [Related]
15. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion-spheronization.
Goyanes A; Martínez-Pacheco R
Drug Dev Ind Pharm; 2015 Mar; 41(3):362-8. PubMed ID: 24279425
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of microcrystalline cellulose II (MCCII) as an alternative extrusion-spheronization aid.
Rojas J; Kumar V
Pharmazie; 2012 Jul; 67(7):595-7. PubMed ID: 22888514
[TBL] [Abstract][Full Text] [Related]
17. Formulation of ranitidine pellets by extrusion-spheronization with little or no microcrystalline cellulose.
Basit AW; Newton JM; Lacey LF
Pharm Dev Technol; 1999; 4(4):499-505. PubMed ID: 10578503
[TBL] [Abstract][Full Text] [Related]
18. The evaluation of formulations for the preparation of pellets with high drug loading by extrusion/spheronization.
Podczeck F; Knight P
Pharm Dev Technol; 2006; 11(3):263-74. PubMed ID: 16895837
[TBL] [Abstract][Full Text] [Related]
19. Use of к-carrageenan, chitosan and Carbopol 974P in extruded and spheronized pellets that are devoid of MCC.
Valle BL; Omwancha WS; Neau SH; Wigent RJ
Drug Dev Ind Pharm; 2016 Nov; 42(11):1903-16. PubMed ID: 27100683
[TBL] [Abstract][Full Text] [Related]
20. Control of drug release by incorporation of sorbitol or mannitol in microcrystalline-cellulose-based pellets prepared by extrusion-spheronization.
Goyanes A; Souto C; Martínez-Pacheco R
Pharm Dev Technol; 2010 Dec; 15(6):626-35. PubMed ID: 20148708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
